

Notice of Allowability

Application No.

10/673,538

Examiner

Maureen M. Wallenhorst

Applicant(s)

LIU ET AL.

Art Unit

1743

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment received on May 12, 2006.
2. ☒ The allowed claim(s) is/are 1, 5-8, 13, 35, 2-4, 9-12, 26-30, 32-33 (renumbered 1-21).
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some* c) ☐ None of the:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input checked="" type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____. |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____. |

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Vickie Sandberg on July 14, 2006.

On page 14, line 19 of the specification, the abbreviation "9-BBN" was changed to -9-borabicyclononane (9-BBN)—in order to provide the full meaning for this compound. On page 14, line 21 of the specification, the phrase "sodium, alkyl sodium and alkyl lithium" was changed to -metallic sodium, metallo-organic alkyl sodium and metallo-organic alkyl lithium—since these types of compounds represent strong reducing agents as used in the instant invention as opposed to just sodium by itself, alkyl sodium by itself or alkyl lithium by itself.

On line 8 of claim 1, the abbreviation "9-BBN" was changed to -9-borabicyclononane (9-BBN)—in order to provide the full meaning for this compound. On lines 9-10 of claim 1, the phrase "sodium, alkyl sodium and alkyl lithium" was changed to -metallic sodium, metallo-organic alkyl sodium and metallo-organic alkyl lithium—since these types of compounds represent strong reducing agents as used in the instant invention as opposed to just sodium by itself, alkyl sodium by itself or alkyl lithium by itself.

On line 10 of claim 9, the abbreviation "9-BBN" was changed to -9-borabicyclononane (9-BBN)—in order to provide the full meaning for this compound. On line 11 of claim 9, the

Art Unit: 1743

phrase “sodium, alkyl sodium and alkyl lithium” was changed to –metallic sodium, metallo-organic alkyl sodium and metallo-organic alkyl lithium—since these types of compounds represent strong reducing agents as used in the instant invention as opposed to just sodium by itself, alkyl sodium by itself or alkyl lithium by itself.

On line 10 of claim 12, the abbreviation “9-BBN” was changed to –9-borabicyclononane (9-BBN)—in order to provide the full meaning for this compound. On line 11 of claim 12, the phrase “sodium, alkyl sodium and alkyl lithium” was changed to –metallic sodium, metallo-organic alkyl sodium and metallo-organic alkyl lithium—since these types of compounds represent strong reducing agents as used in the instant invention as opposed to just sodium by itself, alkyl sodium by itself or alkyl lithium by itself.

On line 10 of claim 26, the abbreviation “9-BBN” was changed to –9-borabicyclononane (9-BBN)—in order to provide the full meaning for this compound. On line 11 of claim 26, the phrase “sodium, alkyl sodium and alkyl lithium” was changed to –metallic sodium, metallo-organic alkyl sodium and metallo-organic alkyl lithium—since these types of compounds represent strong reducing agents as used in the instant invention as opposed to just sodium by itself, alkyl sodium by itself or alkyl lithium by itself.

On line 9 of claim 29, the abbreviation “9-BBN” was changed to –9-borabicyclononane (9-BBN)—in order to provide the full meaning for this compound. On lines 10-11 of claim 29, the phrase “sodium, alkyl sodium and alkyl lithium” was changed to –metallic sodium, metallo-organic alkyl sodium and metallo-organic alkyl lithium—since these types of compounds represent strong reducing agents as used in the instant invention as opposed to just sodium by itself, alkyl sodium by itself or alkyl lithium by itself.

Art Unit: 1743

On line 10 of claim 32, the abbreviation “9-BBN” was changed to –9-borabicyclononane (9-BBN)—in order to provide the full meaning for this compound. On line 11 of claim 32, the phrase “sodium, alkyl sodium and alkyl lithium” was changed to –metallic sodium, metallo-organic alkyl sodium and metallo-organic alkyl lithium—since these types of compounds represent strong reducing agents as used in the instant invention as opposed to just sodium by itself, alkyl sodium by itself or alkyl lithium by itself.

On line 9 of claim 33, the abbreviation “9-BBN” was changed to –9-borabicyclononane (9-BBN)—in order to provide the full meaning for this compound. On lines 10-11 of claim 33, the phrase “sodium, alkyl sodium and alkyl lithium” was changed to –metallic sodium, metallo-organic alkyl sodium and metallo-organic alkyl lithium—since these types of compounds represent strong reducing agents as used in the instant invention as opposed to just sodium by itself, alkyl sodium by itself or alkyl lithium by itself.


2. Reasons for allowance can be found in the Office action mailed on February 22, 2006.

Art Unit: 1743

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maureen M. Wallenhorst whose telephone number is 571-272-1266. The examiner can normally be reached on Monday-Thursday from 6:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jill Warden, can be reached on 571-272-1267. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Maureen M. Wallenhorst
Primary Examiner
Art Unit 1743

mmw

July 17, 2006